Startseite>>Signaling Pathways>> Chromatin/Epigenetics>> HDAC>>SW-100

SW-100

Katalog-Nr.GC64968

SW-100, ein selektiver Inhibitor der Histon-Deacetylase 6 (HDAC6) mit einem IC50 von 2,3 nM, zeigt eine mindestens 1000-fache SelektivitÄt fÜr HDAC6 im Vergleich zu allen anderen HDAC-Isozymen.

Products are for research use only. Not for human use. We do not sell to patients.

SW-100 Chemische Struktur

Cas No.: 2126744-35-0

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
198,00 $
Auf Lager
5mg
180,00 $
Auf Lager
10mg
261,00 $
Auf Lager
50mg
639,00 $
Auf Lager
100mg
1.080,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents

SW-100, a selective histone deacetylase 6 (HDAC6) inhibitor with an IC50 of 2.3 nM, shows at least 1000-fold selectivity for HDAC6 relative to all other HDAC isozymes. SW-100 displays a significantly improved ability to cross the blood-brain-barrier[1].

SW-100 (0.01-10 µM; 48 hours) shows obvious increase in the acetylated α-tubulin levels in a dose-dependent manner[1].

SW-100 (20 mg/kg; i.p.; twice a day for two days) ameliorates several memory and learning impairments including novel object recognition, temporal ordering, and coordinate and categorical spatial processing in mouse model of Fragile X syndrome[1].

[1]. Kozikowski AP, et al. Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and LearningImpairments in a Mouse Model of Fragile X Syndrome. ACS Chem Neurosci. 2019 Mar 20;10(3):1679-1695.

Bewertungen

Review for SW-100

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for SW-100

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.